BUY Glenmark Pharmaceuticals — Amit Seth
byAmit SethHorizon: NA (inferred Swing (≤2wk))11 Aug 2026via CNBC Awaaz.
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
3 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days
Advisor consensus · adjacent horizon·11 Aug · 1w ago
1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days
Advisor consensus · same horizon·12 Aug · 1w ago
Glenmark Pharma Q1 Revenue Beats Estimates, EBITDA Margins Seen Rising
NewsGoogle News·4 Aug · 2w ago
Glenmark Pharma's India-US Growth Story Intact, Says Motilal Oswal, Maintaining 'Buy' — Check Target Price
NewsNdtv-Profit·4 Aug · 2w ago
Glenmark Pharma Q1 profit jumps over 10-fold as India, North America businesses power growth
NewsCnbc-Tv18·31 Jul · 3w ago
Glenmark USA has agreed to a settlement of $15.28 million to resolve antitrust and consumer protection lawsuits related to price-fixing allegations. The company denies all allegations and states the s
BSE · Company Update·11 Aug · 1w ago
Glenmark Pharma Q1 FY27 Results and Brokerage Outlook
NewsGoogle News·4 Aug · 2w ago
Glenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
NSE · Outcome of Board Meeting·31 Jul · 3w ago
The Board of Directors has considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026
BSE · Board Meeting·31 Jul · 3w ago
Glenmark Pharma US arm agrees to $15.28 million settlement with Humana over antitrust lawsuits
NewsCnbc-Tv18·12 Aug · 1w ago
1 other SEBI-registered advisor has an active swing SELL call on this stock, issued in the last 14 days
Advisor consensus · same horizon·7 Aug · 2w ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.